Chloroquine

Generic Name: Chloroquine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₆ClN_₃

CAS Number: 54-05-7

Unique Ingredient Identifier: 886U3H6UFF

Background: Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other c...

Indication: Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
...

Associated Conditions: Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria

Associated Therapies: -

Clinical Trials

Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19

Phase 3

Completed

Conditions: COVID-19
SARS-CoV 2
Coronavirus
COVID
Corona Virus Infection

Interventions: Other: standard care
Drug: Chloroquine
Drug: Hydroxychloroquine

First Posted Date: 2020-06-09

Last Posted Date: 2021-05-12

Lead Sponsor: Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva

Target Recruit Count: 142

Registration Number: NCT04420247

Locations: 🇧🇷
Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva, Curitiba, Parana, Brazil

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

Phase 1

Active, not recruiting

Conditions: Glioblastoma
Gliosarcoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy (IMRT)
Drug: Temozolomide
Drug: Chloroquine
Procedure: Tumor Treating Fields Therapy (TTF)

First Posted Date: 2020-05-21

Last Posted Date: 2024-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT04397679

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria

Phase 3

Terminated

Conditions: Malaria

Interventions: Drug: Pyronaridine - artesunate
Drug: Chloroquine

First Posted Date: 2020-04-30

Last Posted Date: 2022-01-26

Lead Sponsor: Medicines for Malaria Venture

Target Recruit Count: 30

Registration Number: NCT04368910

Locations: 🇰🇷
Inje University Ilsan Paik Hospital, Goyang-si, Korea, Republic of
🇰🇷
Eulji General Hospital, Seoul, Korea, Republic of

PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

Phase 4

Terminated

Conditions: Sars-CoV2
Covid-19
Symptomatic Condition

Interventions: Drug: Placebo
Drug: Hydroxychloroquine Sulfate Regular dose
Drug: Hydroxychloroquine Sulfate Loading Dose
Drug: Chloroquine

First Posted Date: 2020-04-17

Last Posted Date: 2021-03-10

Lead Sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department

Target Recruit Count: 137

Registration Number: NCT04351191

Locations: 🇵🇰
Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan
🇵🇰
Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan
🇵🇰
Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan

and more 1 locations

Efficacy of Faviprevir in COVID-19 Treatment

Phase 2

Completed

Conditions: COVID

Interventions: Drug: Favipiravir
Drug: Chloroquine

First Posted Date: 2020-04-17

Last Posted Date: 2021-11-01

Lead Sponsor: Tanta University

Target Recruit Count: 92

Registration Number: NCT04351295

Locations: 🇪🇬
Tanta University, Ainshams University, Tanta, Egypt

Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

Phase 2

Terminated

Conditions: Coronavirus Infection
COVID

Interventions: Drug: Placebo oral tablet
Drug: Chloroquine

First Posted Date: 2020-04-16

Last Posted Date: 2024-08-13

Lead Sponsor: Columbia University

Target Recruit Count: 8

Registration Number: NCT04349371

Locations: 🇺🇸
Columbia University Irving Medical Center/NYP, New York, New York, United States

Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

Phase 4

Terminated

Conditions: Coronavirus Infection
Asymptomatic Condition
SARS-CoV-2
COVID-19

Interventions: Drug: Hydroxychloroquine Sulfate Regular dose
Drug: Hydroxychloroquine Sulfate Loading Dose
Drug: Placebo
Drug: Chloroquine

First Posted Date: 2020-04-15

Last Posted Date: 2021-03-10

Lead Sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department

Target Recruit Count: 125

Registration Number: NCT04346667

Locations: 🇵🇰
Mayo Hospital, Lahore, Punjab, Pakistan
🇵🇰
Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan
🇵🇰
Expo Covid Center, Lahore, Punjab, Pakistan

Chloroquine for Mild Symptomatic and Asymptomatic COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Other: standard care
Drug: chloroquine

First Posted Date: 2020-04-03

Last Posted Date: 2020-10-14

Lead Sponsor: HaEmek Medical Center, Israel

Target Recruit Count: 5

Registration Number: NCT04333628

Locations: 🇮🇱
Haemek Medical Center, Afula, Israel

Chloroquine as Antiviral Treatment in Coronavirus Infection 2020

Phase 4

Completed

Conditions: COVID-19

Interventions: Other: Telemedicine
Drug: Chloroquine phosphate

First Posted Date: 2020-04-02

Last Posted Date: 2021-02-11

Lead Sponsor: Wroclaw Medical University

Target Recruit Count: 16

Registration Number: NCT04331600

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland
🇵🇱
Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland

The Vietnam Chloroquine Treatment on COVID-19

Phase 2

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Drug: Chloroquine phosphate

First Posted Date: 2020-03-31

Last Posted Date: 2021-05-24

Lead Sponsor: Oxford University Clinical Research Unit, Vietnam

Target Recruit Count: 10

Registration Number: NCT04328493

Locations: 🇻🇳
Cho Ray Hospital, Ho Chi Minh City, Vietnam
🇻🇳
Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam
🇻🇳
Can Gio COVID Hospital, Ho Chi Minh City, Vietnam

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy